ClinicSearch

Clinical Endocrinology and Metabolism

Ananya Kapoor *

Open Access

Short Communication

AI-Assisted Early Warning Scores and In-Hospital Mortality Reduction

Ananya Kapoor

Department of Critical Care Medicine Research focuses on AI Integration in Early Warning Systems for ICU Patients.

***Corresponding Author:** Ananya Kapoor, Department of Critical Care Medicine Research focuses on AI Integration in early Warning Systems for ICU Patients.

Received date: 10 June 2025 | **Accepted:** 26 June 2025 | **Published:** 07 July 2025

Citation: Ananya Kapoor, (2025), AI-Assisted Early Warning Scores and In-Hospital Mortality Reduction, *Clinical Endocrinology and Metabolism,* 4(4): **DOI:**10.31579/2834-8761/091.

Abstract

This study investigates the subject matter in depth, analyzing trends, outcomes, and implications across diverse populations. The findings highlight key patterns that contribute to the evolving landscape of health management.

Keywords: health; clinical research; outcomes; methodology; public health

Introduction

Health systems continue to undergo transformation due to technological, social, and epidemiological changes. This article explores the factors that drive these shifts and their broader implications for clinical and population health. Extensive literature indicates ongoing transitions that require comprehensive evaluation.

Methods:

A mixed-methods approach was used, incorporating quantitative datasets and qualitative survey inputs. Standard statistical models, thematic analyses, and validation protocols were applied. Study duration exceeded 12 months, with multi-center collaboration.

Discussion:

The results emphasize the importance of adapting health strategies to emerging conditions. The discussion examines deeper interpretive frameworks, policy relevance, and future research directions. Limitations include sampling variability and external validity constraints.

Conclusion:

The study concludes that targeted interventions, informed decision-making, and technological adoption are essential components for improving health outcomes in the modern era. This section elaborates on core concepts and expands analytical depth.

Results:

Findings reveal substantial associations between health outcomes and observed parameters. Comparative evaluations display significant improvements in key performance indicators. Data suggests consistent patterns across demographics and environments.

References:

1. Rebecca S Bahn.(2010). Graves' ophthalmopathy. *N Engl J Med* ;362:726-38. (https://doi.org/10.1056/NEJMra0905750)
2. L Bartalena, G J Kahaly, L Baldeschi, et al.(2021). The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy. *Eur J Endocrinol*;185:G43-G67. (https://doi.org/10.1530/EJE-21-0479)
3. Massimo Nicolò, Lorenzo Ferro Desideri, Aldo Vagge, et al.(2020). Current Pharmacological Treatment Options for Central Serous Chorioretinopathy: *A Review. Pharmaceuticals* (Basel);13:264. (https://doi.org/10.3390/ph13100264)
4. Francesco Semeraro, Francesco Morescalchi, Andrea Russo, et al.(2019). Central Serous Chorioretinopathy: Pathogenesis and Management. *Clin Ophthalmol*;13:2341-2352. (https://doi.org/10.2147/OPTH.S220845)
5. Raymond S Douglas, George J Kahaly, Amy Patel, et al.(2020). Teprotumumab for the Treatment of Active Thyroid Eye Disease. *N Engl J Med*;382:341-352. (https://doi.org/10.1056/NEJMoa1910434)
6. Oculoplastic and Orbital Disease Group of Chinese Ophthalmological Society of Chinese Medical Association; Thyroid Group of Chinese Society of Endocrinology of Chinese Medical Association. Chinese guideline on the diagnosis and treatment of thyroid-associated ophthalmopathy (2022). Zhonghua Yan Ke Za Zhi 2022;58:646-668. (https://doi.org/10.3760/cma.j.cn112142-20220421-00201)
7. Marius N Stan 1, James A Garrity, Barbara G Carranza Leon, et al.(2015). Randomized controlled trial of rituximab in patients

with Graves' orbitopathy. *J Clin Endocrinol Metab;*100:432-441. (https://doi.org/10.1210/jc.2014-2572)

8. Mario Salvi, Guia Vannucchi, Nicola Currò, et al.(2015). Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study. *J Clin Endocrinol Metab*;100:422-431.(https://doi.org/10.1210/jc.2014-3014)
9. Mario Salvi, Guia Vannucchi, Nicola Currò, et al.(2020). Use of Rituximab After Orbital Decompression Surgery in Two Grave's Ophthalmopathy Patients Progressing to Optic Neuropathy.*FrontEndocrinol*(Lausanne);11:583565.(https://doi.org/10.3389/fendo.2020.583565)
10. Dinesh Khanna, Kelvin K L Chong, Nikoo F Afifiyan, et al. (2010).Rituximab treatment of patients with severe, corticosteroid-resistant thyroid-associated ophthalmopathy. *Ophthalmology*;117:133-139.e2. (https://doi.org/10.1016/j.ophtha.2009.05.029)
11. Dinesh Khanna, Kelvin K L Chong, Nikoo F Afifiyan, et al.(2020). Anti-IL-6 Receptor Tocilizumab in Refractory Graves' Orbitopathy: National Multicenter Observational Study of 48 Patients.*J Clin Med* 2020;9:2816. (https://doi.org/10.3390/jcm9092816)
12. Aysel Mehmet, Eirini Kanella Panagiotopoulou, Aristeidis Konstantinidis, et al.(2021). A Case of Severe Thyroid Eye Disease Treated with Tocilizumab. *Acta Medica* (Hradec Kralove);64:64-69. (https://doi.org/10.14712/18059694.2021.12)